RARE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Ultragenyx Pharmaceutical Inc (RARE) is not a strong buy for a beginner, long-term investor at this time. The stock faces significant challenges, including insider selling, ongoing class action lawsuits, and weak financial performance. While analysts maintain generally positive ratings with reduced price targets, the lack of strong technical signals and negative sentiment from lawsuits make this a hold rather than a buy.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 57.775, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of R1: 23.81, suggesting limited upside in the short term.
Revenue increased by 25.72% YoY in Q4 2025, showing growth in sales. Analysts expect positive Phase 3 GTX-102 data for Angelman syndrome in 2H26, which could be a key inflection point for the stock.
Insider selling has increased significantly by 2368.07% over the last month. The company is facing multiple class action lawsuits related to securities fraud, which could negatively impact investor sentiment. Financial performance shows declining net income, EPS, and gross margin YoY. The stock has a 70% chance of a slight decline (-0.93%) in the next day.
In Q4 2025, revenue grew by 25.72% YoY to $207.3M. However, net income dropped by -3.62% YoY to -$128.6M, and EPS fell by -7.19% YoY to -1.29. Gross margin also declined by -4.36% YoY to 85.84%.
Analysts maintain generally positive ratings with reduced price targets. Recent price targets range from $34 to $79, reflecting mixed sentiment. Analysts highlight cost-cutting measures and upcoming clinical data as potential positives but note regulatory risks and uneven revenue growth.
